The technology described pertains to the development of bispecific antibodies with enhanced ability to neutralize HIV-1. By structurally designing single chain fragment variable antibodies that join variable regions of multiple broadly neutralizing antibodies (bNAbs) with flexible linkers, the research has yielded a bispecific antibody that targets different epitopes on the HIV-1 envelope. The combination of VRC01—targeting the CD4 binding site—and PGT121—targeting the V3 glycan—has shown promising results. In tests against a stringent virus panel, the optimized VRC01-PGT121 bispecific antibody demonstrated 100% coverage and potent neutralization of HIV-1, suggesting a significant advancement in HIV-1 therapeutic strategies.